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Abstract
X  .We previously reported that a mutation in a 3 enhancer region of the a -antitrypsin AAT gene is associated with1
 .chronic obstructive airways disease COAD . During the acute-phase response the plasma concentration of AAT increases
 .approximately 3-fold and this effect is mediated primarily by interleukin-6 IL-6 . We demonstrate, by transfection of Hep
G2 cells, that the AAT gene contains at least two enhancers, one at the 5X end of the gene which is dominant under basal
conditions, and another at the 3X end of the gene which exhibits weak basal activity. However, both enhancers must be
present to modulate the IL-6-induced response which is diminished as a consequence of the 3X enhancer mutation. These
results suggest that the 3X enhancer modulates the IL-6 response through an interaction with the 5X enhancer. The mutation
 .occurs at a DNA binding site for the ubiquitous transcription factor octamer-1 Oct-1 and results in a loss of cooperativity
 .between Oct-1 and the tissue-specific transcription factor, NF-IL6 CrEBPb , a member of the CrEBP family of
transciption factors. NF-IL6 is a key transcription factor for a major pathway through which IL-6 mediates its effects. These
observations provide a novel mechanism for a diminished IL-6-induced response. q 1997 Elsevier Science B.V.
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1. Introduction
COAD affects about 3% of the population in
w xwestern countries 1 and in about 20% of cases, there
is a strong familial component which is predomi-
Abbreviations: AAT, a -antitrypsin; CAT, chloramphenicol1
acetyltransferase; COAD, chronic obstructive airways disease;
IL-6, interleukin-6; NF-IL6, nuclear factor for interleukin-6; Oct-
1, Octamer 1 protein
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w xnantly genetic in origin 2 . Genetic deficiency of
AAT results in a 20-fold increased risk of developing
chronic progressive lung damage in cigarette smokers
and occurs in approximately 1 in 3000 individuals of
w xnorthern european descent 3 . AAT plays a major
role in protecting the lower respiratory tract from
damage mediated by neutrophil proteinases, in partic-
ular, elastase.
We previously identified a mutation in a 3X en-
hancer sequence of the AAT gene which occurs in
w xabout 17% of patients with COAD 4,5 an observa-
w xtion confirmed by others 6 and is thus a common
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predisposing genetic factor for the development of
disease. The basal plasma concentration and protein
type of AAT is normal in individuals with the muta-
w xtion 4 . During inflammation there is a 3–4-fold rise
in the plasma AAT concentrations and this phe-
nomenon is referred to as the acute-phase response.
This response is mediated principally by the cytokine
IL-6, which in turn exerts its effects via transcription
w xfactors of the CrEBP family 7,8 . The COAD-asso-
 .ciated mutation occurs in an octamer-1 Oct-1 bind-
ing site and there are a number of other potential
regulatory elements nearby, including a CrEBP con-
sensus sequence. It is not known if patients who have
the mutation show reduced levels of AAT during
inflammation.
The acute-phase response shows temporal and in-
dividual variation and it is therefore difficult to per-
form reliable clinical studies to measure the increase
of circulating AAT levels during inflammation. To
overcome this, we investigated the IL-6 response of
cells transfected with wild-type and mutant AAT
gene regulatory sequence and the binding character-
istics and interactions of nuclear transcription factors
to this region. The mutation caused a loss of response
to IL-6 and thus would be expected to result in a
diminished acute-phase response in vivo. We provide
experimental evidence that the molecular mechanism
for this effect is the loss of cooperative binding
between the tissue-specific transcription factor NF-
 .IL6 also known as CrEBPb , a major positive
acting member of the CrEBP family of transcription
factors and the ubiquitous transcription factor Oct-1.
2. Materials and methods
2.1. Transfection constructs
All constructs utilised the pCAT SV40 promoter
 .plasmid Promega with the following AAT frag-
 . Xments cloned into this vector: i 5 -pCAT contained
X the 5 AAT enhancer from y270 to y30, number-
w x.ing system from transcription start site 9 inserted
 . Xupstream of the CAT gene; ii 3 WT-pCAT con-
X  .tained the 3 wild-type AAT enhancer 11173–11542
 . Xinserted downstream of the CAT gene; iii 3 MUT-
pCAT contained the 3X mutant AAT enhancer in-
 . X Xserted downstream of the CAT gene; iv 5 q3
WT-pCAT contained both the 5X and 3X wild-type
AAT enhancers inserted upstream and downstream of
 . X Xthe CAT gene, respectively; v 5 q3 MUT-pCAT
contained both the 5X and 3X mutant AAT enhancers
 .as in iv above. A physical map of the pCAT SV40
promoter plasmid, together with the regions of the
AAT gene utilised, is shown in Fig. 1. The AAT 5X
and 3X enhancer elements for cloning into the pCAT
SV40 promoter plasmid were generated by PCR us-
ing oligonucleotides which incorporated the requisite
restriction sites. In all experiments both enhancers
were in the sense orientation. All the constructs had
their sequence confirmed in both directions. The
pCAT SV40 promoter plasmid without any enhancer
activity, together with the pCAT SV40 promoter and
enhancer plasmid were used as positive controls. The
data are expressed as fold increase over the pCAT
SV40 promoter, which represents the increase in
activity compared to that obtained with the pCAT
SV40 promoter plasmid alone.
Fig. 1. Physical map of the Promega pCAT SV40 promoter
 .plasmid engineered to test for enhancer activity and the AAT
gene indicating the regions cloned and the restriction sites utilised.
X  .The AAT 5 enhancer from y30 to y270 was cloned into the
Bg1 II site upstream of the SV40 promoterrCAT gene and the
X  .AAT 3 enhancer 11173–11542 was cloned into the Bam
H1rPst 1 sites downstream of the CAT gene. In all the experi-
ments reported, both inserts were in the sense orientation.
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2.2. Transfection of Hep G2 cells
Hep G2 cells were seeded onto 60 mm plates in
 .5 ml of Eagles’ minimum essential medium MEM
containing 10% bovine calf serum, 5%
penicillinrstreptomycin, 5% L-glutamine and 5%
 .  .fungizone complete MEM Gibco BRL . The cells
were incubated in a humidified atmosphere of 5%
CO in air at 378C for 24 h. The cells were grown to2
40–50% confluency before transfection. Three hours
prior to transfection, the cells were fed with 4.5 ml
fresh complete MEM.
Transfections were performed by calcium phos-
 .phate co-precipitation Gibco BRL using the con-
structs outlined above, and the final DNA concentra-
tion in all cases was 1 mgrml. In co-transfection
experiments with a b-galactosidase reporter gene
construct, we have previously shown that transfection
efficiencies are highly reproducible at this concentra-
w xtion of DNA 5 . After 24 h, the media was removed
and replaced with fresh complete MEM. The cells
were either harvested 48 h later, or recombinant hu-
 .man lL-6 Promega at 30 ngrml and 90 ngrml was
added 24 h later, and the cells left a further 20 h
before harvesting. The controls for these experiments
were the pCAT SV40 promoter plasmid with the
relevant concentration of IL-6. CAT reporter gene
activity was measured in triplicate using 14C chlor-
amphenicol as substrate following the Promega CAT
enzyme assay protocol. Freshly harvested cells were
subjected to three cycles of freezingrthawing, the
samples were microfuged and the supernatants stored
at y808C until assay. 25ml of cell extract was
incubated for 1 h at 378C with 90 ml of 250 mM Tris
14  .pH 8.0, 5ml of C chloramphenicol 0.025 mCirml
 .and 5 ml n-butyryl coenzyme A 5 mgrml . The reac-
tion was terminated by the addition of 300 ml xylene.
The xylene phase was back extracted with 100 ml of
250 mM Tris pH 8.0 and 200 ml of the xylene phase
mixed with 2 ml of Betamax ES scintillant ICN
.Flow and counted for 1 min in an LKB beta counter,
w xas previously described 5 .
( )2.3. Amplification of wild-type WT and mutant
( )MUT AAT DNA fragments
 .Probes 100 bp suitable for analysis in gel-shift
assays were amplified using 20 ng template DNA as
w xdescribed previously 10 . The PCR products were
cleaned using QIAquick PCR purification columns
 .Qiagen and the DNA concentration determined by
measuring absorbance at 260 nm, using a spectro-
 .photometer Pharmacia GeneQuant designed for
DNA quantification. The sequence across the muta-
tion site in both the wild-type and mutant 100 bp
fragments was verified by cycle sequencing of the
 .PCR products Gibco BRL using extension from the
X  . w 32 x5 amplimer P end-labelled with g- P ATP and1
T polynucleotide kinase.4
2.4. Nuclear mini-extract preparation
HeLa and Hep G2 cells were cultured in MEM
medium supplemented with 10% fetal calf serum,
100 IUrml penrstrep, 2 mM L-glutamine and
 .2.5 mgrml fungizone Gibco BRL . Cells were incu-
bated at 378C, 100% humidity, 5% CO in air. Hep2
G2 cells were treated with human recombinant IL-6
 .Promega at a final concentration of 60 ngrml for
20 h. Nuclear mini-extracts were prepared from
freshly harvested cells using the method of Schreiber
w xet al 11 . All extracts were stored in aliquots at
y808C.
2.5. Gel-shift analysis
 XThe OCT DNA consensus sequence 5 -TGT CGA
X.ATG CAA ATC ACT AGA A-3 was obtained from
 XPromega and the CrEBP consensus 5 -TGC AGA
X.TTG CGC AAT CTG CA-3 from Santa Cruz
Biotechnology. Antibodies specific for Oct-1,
CrEBPa and NF-IL-6 were also purchased from
Santa Cruz Biotechnology. 2 pmol of each consensus
together with 2 pmol of AAT 100 bp WT were end-
labelled for use as gel-shift probes. All probes were
cleaned by applying the aqueous phase from phenol
extracted labelling reactions to a Sephadex G50 spin
column equilibrated in TE buffer 10 mM Tris, 1 mM
.EDTA, pH 7.6 . Binding reactions were performed
by incubating 40 fmol of radio-labelled probe in low
salt binding buffer 100 mM NaCl, 3 mM MgCl ,2
.50 mM Tris–HCl, pH 8.0 containing 1 mg poly
 .dIdC and 2 ml of HeLa or IL-6 Hep G2 nuclear
extract for 60 min on ice. Reactions containing 50-fold
motor excess of OCT were pre-incubated for 30 min
on ice. ‘‘Super-shift’’ assays using the antibodies
were also preincubated on ice for 60 min in the above
reaction mix before the addition of the radio-labelled
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probe. For the competitive displacement gel-shift as-
says wild-type and mutant 100 bp AAT fragments
were added at 2–100-fold molar excess and preincu-
bated 30 min on ice before the addition of the appro-
priate radio-labelled consensus sequence; the 2–100-
fold AAT titrations containing 50-fold molar excess
CrEBP were also preincubated 30 min on ice. The
signal intensity with the IL-6 Hep G2 extract, in the
absence of CrEBP, was used as a control value and
normalised to 100%. At the end of the binding reac-
 .tion 2 ml of 0.1% wrv bromophenol blue in 5%
glycerol was added to each tube. The samples were
subjected to electrophoresis in 4% HeLa experi-
.  .ments or 6% IL-6 Hep G2 polyacrylamide using
chilled 0.25 = TBE buffer 22 mM Tris–borate,
.0.5 mM EDTA, pH 8.0 . The gel was dried and then
exposed to pre-flashed X-ray film for 18 h at y808C
using CaWO intensifying screens. The autoradio-4
graphs were scanned with a Beckman Appraise auto-
mated densitometer.
3. Results
3.1. Transfection studies
There were no discernible differences between the
5X enhancer alone and either of the constructs contain-
ing both enhancers, i.e. the 5X enhancer together with
X  .the wild-type or mutant 3 enhancer Fig. 2 a . All of
these constructs resulted in a 6.5-fold increase of the
pCAT promoter control plasmid. In contrast, the
wild-type 3X enhancer demonstrated weak activity
 . X1.8-fold increase over promoter and the mutant 3
Fig. 2. Transfection of human Hep G2 cells with constructs
containing the 5X andror 3X AAT enhancers: loss of IL-6 stimula-
X  .tion due to the 3 AAT enhancer mutation: a effect of the
constructs on CAT gene expression under basal conditions. 5Xr3X
WT s 5X AAT enhancer, together with the wild-type 3X enhancer.
5Xr3X MUT s 5X AAT enhancer, together with the mutant 3X
enhancer. A small increase in activity is observed with the 3X WT
 X .construct, which is lost with the mutant sequence 3 MUT . The
5Xr3X WT, 5Xr3XMUT and 5X alone constructs all demonstrated
 .the same level of CAT gene activation ;6.5-fold above that
obtained with the pCAT SV40 promoter alone. No effect was
observed due to the presence of the 3X mutation, indicating that
X  .the 5 enhancer is dominant under basal conditions; b the effects
 .of stimulation with IL-6 30 ngrml and 90 ngrml on CAT gene
expression. A mean increase of 18.9-fold and 28.0-fold, respec-
tively, over the pCAT SV40 promoter was seen with the 5Xr3X
 . WT construct ‘–‘ this equates to a 3–4-fold increase over
 .basal, i.e. above the values shown in Fig. 2 a , and represents the
. X  .IL-6 inducible component ; the 5 construct alone ’-’ had a
9.9-fold and 12.4-fold increase over the pCAT SV40 promoter
this equates to from one-and-a-half to two-fold increase over
. X X  .basal . The 5 r3 MUT I-I construct demonstrated a similar
X  .increase over the pCAT SV40 promoter as the 5 WT ^-^
X  . X  .construct. The 3 WT v-v and 3 MUT ’-’ both demon-
strated weak enhancer activities. No activation was observed with
 .the pCAT SV40 promoter plasmid alone e-e . Results depicted
are mean" SEM of at least three experiments performed in
triplicate.
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enhancer was inactive i.e. value was the same as the
.pCAT promoter control . Under basal conditions the
5X enhancer of the AAT gene was dominant as mea-
 .sured by chloramphenicol acetyl transferase CAT
reporter gene activity in Hep G2 cells. However, in
 .response to IL-6 Fig. 2 b , CAT activity was in-
 .creased up to 28-fold at 90 ngrml IL-6 in Hep G2
cells transfected with DNA constructs containing both
enhancers, but to a much lesser extent around 10-
. Xfold in constructs containing only the 5 enhancer or
the 5X enhancer together with the mutant 3X enhancer
and minimal inducibility for both the mutant and
wild-type 3X enhancers. IL-6 had minimal effect on
the activity of the pCAT SV40 promoter plasmid.
These results demonstrate that the IL-6 induced in-
crease required the presence of both enhancers and
was lost in the presence of the mutant 3X AAT
enhancer. Thus, the 3X enhancer appears to be essen-
tial for mediating the 3–4-fold up-regulation associ-
ated with the acute-phase response but the 5X en-
 .hancer which on its own has around a 2-fold effect
must also be present in order for full stimulation to
be seen. The only difference between the wild-type
and mutant enhancer constructs is the single base
change at the Oct-1 binding site. Since this mutation
 .results in a deficient IL-6 response Fig. 1 b there
might be ‘‘cross-talk’’ between Oct-1 and IL-6 in-
ducible transcription factors, i.e. NF-IL6 when bound
to the AAT 3X enhancer. To understand the mecha-
nism of this effect we explored the binding of tran-
scription factors to the region containing the muta-
tion.
( )3.2. Transcription factor Oct-1 binding
Since the mutation occurs in an ‘‘octamer-like’’
motif, we initially investigated the binding of Oct-1
 .protein to this region Fig. 3 a . HeLa cell nuclear
extract was used as it is a good source of ubiquitous
transcription factors including Oct-1. Experiments
were also performed with Hep G2 cells, both before
and after stimulation with IL-6. Using the octamer
 .DNA consensus sequence OCT as a probe, HeLa
extract was seen to contain a single species of Oct
protein which could be displaced with a 50-fold
molar excess of cold competing OCT and was ‘‘su-
per-shifted’’ band with slower electrophoretic migra-
.tion using an antibody specific for Oct-1 protein Fig.
 .3 b . By increasing the pre-incubation with antibody
from 1 to 3 h it was possible to ‘‘super-shift’’ all of
 .the Oct-1 present in HeLa extract data not shown .
Similar results were observed for the binding of
Oct-1 to the 100 bp WT AAT gene fragment; it could
be displaced with 50-fold molar excess of cold com-
peting OCT and by pre-incubation with Oct-1 anti-
 . w xbody Fig. 3 b . As had been previously observed 4 ,
other HeLa regulatory proteins bound to the 100 bp
AAT gene fragment. These results demonstrated that
Oct-1 was capable of binding to the wild-type AAT
enhancer. We have obtained similar results using Hep
 .G2 nuclear extracts data not shown .
3.3. Altered Oct-1 binding due to the mutation
We next compared the binding of Oct-1 to wild-
type and mutant AAT gene fragments using a com-
 .petitive displacement gel-shift assay Fig. 3 c and d .
The principle of this approach is that decreased bind-
ing of a particular transcription factor to its radio-
labelled consensus sequence, in the presence of in-
creasing molar excess of competing gene fragment,
 .i.e. the 100 bp AAT fragment Fig. 3 a , is directly
related to the degree to which the transcription factor
binds to the fragment. As more transcription factor
bound to the AAT fragment, so less would be bound
to the radio-labelled consensus sequence, and this
would be reflected as a decreased signal intensity. In
this case, since the radio-labelled octamer consensus
sequence was used, we could detect differences in
Oct-1 protein binding to the AAT gene fragment.
Implicit in this approach is that each point in the
displacement curve, i.e. all reaction tubes, contain
identical amounts of radio-labelled probe and nuclear
extract. All gel-shifts gave identical intensities for
unbound DNA probe at the bottom of the gel, thereby
ensuring equivalent sample loading. Under these con-
ditions, the differences in the displacement patterns in
the competition experiments represent changes in
w xtranscription factor binding affinities 12 . The repro-
ducibility of displacement patterns was verified by
performing densitometric analysis on the results from
experiments conducted on at least three separate oc-
casions with different batches of nuclear extract.
We used HeLa nuclear extract Oct-1 protein bind-
ing to its consensus DNA sequence, since it gave a
 .very strong signal Fig. 3 c , lanes 1–3 and hence
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permitted subtle changes in binding patterns to be
discerned in competition experiments. Increasing
concentrations of 100 bp WT AAT sequence the
.amounts were determined spectrophotometrically
progressively displaced Oct-1 from its consensus se-
 .quence Fig. 3 c . The mutant AAT fragment had a
 .lower affinity for Oct-1 protein Fig. 3 c compared to
the wild-type fragment. This was clearly seen when
the densitometric scans of the wild-type and the
 .mutant autoradiographs were plotted Fig. 3 d ; there
was a pronounced shoulder on the curve with half-
maximum displacement shifting from 3 times com-
peting fragment for wild-type to 7 times for mutant.
The mutant sequence was at least 50% less effective
than the wild-type at displacing Oct-1 from its con-
sensus sequence; we interpreted this difference as
reduced binding affinity due to the mutation at the
octamer site.
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3.4. Positi˝e cooperati˝ity between Oct-1 and NF-IL6
( )an IL-6 induced transcription factor
The loss of binding of Oct-1 in itself would not
explain a defective acute-phase response. Therefore,
we decided to investigate the potential interactions
between regulatory factors at this region, particularly
as a CrEBP consensus sequence which binds NF-
.IL6 had been identified 10 bp downstream of the
 .octamer site Fig. 3 a . These experiments were per-
formed using Hep G2 extracts, after stimulation with
IL-6, since they are known to produce transcription
factors inducible by IL-6, i.e. predominantly NF-IL6.
To ensure that the nuclear mini-extracts prepared
from IL-6 treated Hep G2 cells contained NF-IL6,
gel-shift experiments were performed with CrEBP
consensus sequence and NF-IL6 isoform specific an-
 .tibodies NF-IL6 and NF-IL6b . Specific binding of
NF-IL6 was confirmed using 50-fold molar excess of
‘‘cold’’ unlabelled competing consensus sequence
which resulted in greater than 95% displacement of
NF-IL6 from radioactive CrEBP consensus se-
quence. The displaced band was also ‘‘supershifted’’
by NF-IL6 antibody, but not by NF-IL6b antibody
 .data not shown . Stimulation with IL-6 resulted in an
approximate 2–3-fold increase in the binding activity
of NF-IL6 in Hep G2 cells as previously reported by
w xIsshiki et al 13 . The IL-6 treatment phosphorylates
endogenous NF-IL6, thereby markedly increasing its
binding activity. The displacement of Oct-1 from its
consensus sequence by increasing amounts 2–100-
.fold of 100 bp WT AAT fragment was compared to
that obtained on preincubation with 50-fold molar
excess of CrEBP consensus sequence before the
addition of the 100 bp AAT competing fragment.
This pre-treatment effectively removed all the avail-
able NF-IL6 as it bound to its consensus sequence,
thereby permitting detection of any potential coopera-
tive effect it might be exerting on Oct-1 binding to
the AAT gene fragment. A 50-fold molar excess
CrEBP DNA consensus sequence per se did not
displace Oct-1 from its consensus sequence, demon-
strating that CrEBP had no effect on Oct-1 binding.
The autoradiographs of these gel-shift displacement
 .assays are shown in Fig. 4 a together with the plots
 .of the densitometric scans of this data Fig. 4 b .
However, the data obtained in the presence of a
50-fold molar excess of CrEBP consensus sequence,
showed a dramatic change in the displacement curve
with half-maximal displacement shifting 3–30-fold
molar excess of competing 100 bp AAT fragment
 .Fig. 4 b . These results demonstrate that when IL-6
activated NF-IL6 was removed, thus preventing it
from binding to the AAT fragment, the 100 bp WT
AAT fragment was around ten times less effective at
binding Oct-1; we interpret this as evidence for a
positive cooperative interaction between NF-IL6 and
Oct-1. To confirm that there was an interaction be-
tween NF-IL6 and Oct-1, the AAT titration experi-
ments were repeated using the 100 bp WT AAT
enhancer fragment and nuclear extracts prepared from
Hep G2 cells with and without treatment with recom-
binant human IL-6. The gel-shifts were scanned data
.not shown and the densitometric data obtained are
X  . XFig. 3. Oct-1 protein binding to the AAT gene 3 enhancer; a partial nucleotide sequence of the 3 flanking region of the AAT gene
 .  .  .EMBL accession number X60765 . The regulatory motifs AP1 consensus sequence TGAGTCA , OCT consensus ATTTGCAT and
 .  .CrEBP consensus TKNNGYAAK are shown in boxes, together with the position of the mutation TCGA “ TCAA which is starred
 .  .) . The position of the oligonucleotides P and P used to amplify 100 bp WT and mutant fragments of the AAT gene for use as1 2
 .  .gel-shift probes are indicated by arrows; b gel-shift analysis with HeLa nuclear mini-extracts performed using the octamer OCT DNA
 .  .  .consensus sequence lanes 1–4 and 100 bp WT AAT gene fragment lanes 5–7 as probes. The position of Oct-1 protein is arrowed; c
 .  .interaction of Oct-1 with wild-type WT and mutant MUT 100 bp AAT gene fragments. Competitive gel-shift displacement assays were
 .performed to measure the effect of increasing molar excess 2–100-fold of 100 bp AAT fragments, both WT and MUT, on the binding of
 .  .Oct-1 to its consensus sequence. Typical autoradiographs obtained with WT upper and MUT lower AAT fragments are shown; the
 .  .position of Oct-1 is arrowed; d graphical representation of the densitometric scans of the autoradiographs shown in Fig. 3 c . Results
 .shown mean " SEM are typical of that obtained in three separate experiments, each performed in duplicate using different batches of
 .nuclear extract. Increasing wild-type sequence I-I produced a typical displacement curve with half-maximal displacement being
 .achieved at 3-fold molar excess. In contrast, the pattern obtained with mutant sequence v-v was shifted to the right with a pronounced
shoulder and half-maximal displacement at 7-fold molar excess. All the points of the mutant curve were significantly different P - 0.01,
.students t-test from the wild-type curve, except at 100-fold molar excess, which demonstrated that at this point there was minimal Oct-1
 .binding - 5% to the consensus sequence in the presence of both wild-type and mutant AAT fragments.
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 .Fig. 4. Cooperative effect of NF-IL6 on Oct-1 binding; a
 .interaction of Oct-1 arrowed prepared from IL-6 treated Hep
G2 cells, with 100bp WT AAT fragment in the presence lower
.  .autoradiograph and absence upper autoradiograph of 50-fold
 .excess CrEBP consensus sequence; b plot of the autoradio-
 .graph densitometric scans shown in Fig. 4 a . Pre-incubation with
a 50-fold excess of CrEBP consensus sequence shifted half-max-
 .  .imal displacement of Oct-1 from 3-fold v-v to 30-fold I-I
competing 100 bp WT AAT fragment, thereby demonstrating the
cooperative effect of NF-IL6 on Oct-1 binding. Results shown
 .mean" SEM are typical of that seen in experiments conducted
on at least three separate occasions in duplicate using different
batches of nuclear extract
Fig. 5. Oct-1 binding to the wild-type 3X AAT enhancer using
nuclear extracts prepared from Hep G2 cells with and without
treatment with IL-6 The gel-shift banding patterns for the AAT
titrations were scanned and the densities obtained plotted as
shown. IL-6 treatment resulted in a shift of the curve to the left
 .v-v when compared with the pattern obtained in the absence
 .of IL-6 I-I . These results demonstrate that IL-6 treatment in
Hep G2 cells results in increased Oct-1 binding to the 3X AAT
 .enhancer visualised as a reduced binding to its consensus ; we
interpret this as evidence for an interaction between Oct-1 and
NF-IL6. Results shown are mean" SEM from three separate
experiments performed in duplicate.
shown in Fig. 5. This figure demonstrates that IL-6
treatment of Hep G2 cells, which increases the bind-
ing affinity of NF-IL6, results in greater displacement
of Oct-1 from its consensus curve is shifted to the
.left i.e. under these conditions more Oct-1 is binding
to the 3X AAT enhancer as would be predicted if
NF-IL6 had a cooperative effect on Oct-1 binding.
4. Discussion
We demonstrate that there are two functional en-
hancers in the AAT gene. The 5X enhancer is domi-
nant during basal expression and the 3X enhancer, in
comparison, has a small effect. During IL-6 stimula-
tion, however, the 3X enhancer plays a major role in
concert with the 5X enhancer and this effect is depen-
dent on the 5X enhancer being present, suggesting an
interaction between the two enhancers. The conse-
quence of the mutation in the 3X enhancer is to blunt
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the IL-6 induced response. It must be noted that in
our constructs the spatial arrangement of the two
 .enhancers is much closer 800 bp apart than that
 .seen in the AAT gene over 11 kb apart . Therefore,
it is possible that the situation is different in the intact
AAT gene. However, with a greater distance between
the two enhancers, it can be envisaged that DNA
bending would be easier and, if the two regions do
interact, the ‘‘looping-out’’ model of gene activation
would be supported.
The acute phase response provides a defence
mechanism in any inflammatory process. During this
response, several plasma protein genes are transcrip-
tionally induced. The response is primarily mediated
by cytokines, in particular IL-1 and IL-6. IL-6 is the
major cytokine associated with the increased expres-
sion of AAT in the liver during the acute phase
response. The mechanisms by which IL-6 influence
the expression of AAT are yet to be completely
defined. The IL-6 response can be mediated by two
types of DNA sequences. Type I elements TKN-
.NGYAAK bind transcription factors which are
members of the CrEBP family particularly NF-IL6
w xwhich is activated post-translationally 14 . Another
CrEBP transcription factor, CrEBPa , is a negative
regulator and competes with NF-IL6 for binding.
During the acute-phase response in mouse liver, NF-
IL6 is up-regulated, whereas CrEBPa is down-regu-
w x  .lated 13 . Type II elements TTCNNNGAA , also
 .known as acute-phase response elements APRE , are
 . involved in the JAK Janus Kinase -STAT signal
.transducers and activators of transcription pathway
w x15 . Up-regulation of STAT3 by IL-6 has been
w xdemonstrated in liver cells 14 but its possible role in
AAT gene expression has yet to be explored.
Some insights to explain the loss of binding of
Oct-1 to mutant sequence may be obtained from the
w xcrystal structure of Oct-1 16 . Specific contact points
between amino acid residues in Oct-1 and nucleotide
bases have been identified. Oct-1 protein contains
two domains. The mutation occurs at the contact
region for the POU-specific domain, a DNA-binding
domain which characterises a number of eukaryotic
transcription factors, and originally found in the pitu-
itary specific transcription factor, Pit-1rGHF-1, Oct-1
and Oct-2 and the C. elegans cell linear control gene
unc-86. The POU-specific domain makes contacts in
the major groove, specifically at amino acid residues
Arg 49 and Thr 55. Our data suggest that the base
inversion seen between the consensus sequence AT-
.TTGCAT and the AAT Oct-1 binding sequence
 .ATTTCGAT has minimal effect on Oct-1 binding;
the likely explanation for this is that the protein has
enough flexibility to straddle across the helix and still
maintain contact to the correct nucleotide on the
opposite DNA strand. The two binding domains of
Oct-1, the POU-specific and POU homeodomain, are
tethered by a flexible link which might permit this to
occur. The presence of the mutation at the OCT-like
 .site ATTTCAAT may disrupt these contacts, and
thus alter the affinity of binding of Oct-1 to the AAT
enhancer. We have demonstrated a reciprocal cooper-
ative effect between NF-IL6 and Oct-1 protein bind-
ing sites which provides a mechanism for an apparent
ubiquitous transcription factor, Oct-1, to have a tis-
sue-specific effect due to interaction with a tissue-
 .specific transcription factor NF-IL6 . Currently, we
do not know if Oct-1 binding to this region just has a
stabilising effect on NF-IL6 binding or if there is
absolute specificity for Oct-1, i.e. will other ubiqui-
tous transcription factors produce a similar effect?
However, the functional studies show that the net
effect of disruption of the Oct-1rNF-IL6 interaction
by the 3X AAT enhancer mutation is a diminished
IL-6-induced response. It is unlikely that the 3X AAT
regulating region we describe is part of a neighbour-
ing gene. The next gene downstream of the AAT
gene, approximately 12 kb away, is the AAT pseudo-
gene, which appears not to be expressed. The nearest
w xexpressed gene is about 220 kb away 17 .
During an inflammatory process such as occurs
during lung infection, or in cigarette smokers, neu-
w xtrophils are recruited to the lung 3 . Subsequent
release of the enzyme, neutrophil elastase, if uninhib-
ited, results in damage to the connective tissue of the
lung. It is probable that during inflammation there is
a deficiency of a -antitrypsin relative to the load of1
neutrophil elastase in individuals who carry the muta-
tion. The mutation appears to confer risk to COAD,
in heterozygotes. There may be other mechanisms
which mediate the acute-phase response that are inde-
pendent of IL-6. For example, in rabbit AAT an
enhancer which is responsive to lipopolysaccharide
has been identified approximately 2 kb pairs upstream
w xfrom the transcriptional start site 18 . There is evi-
dence to suggest that increased AAT protein produc-
( )K. Morgan et al.rBiochimica et Biophysica Acta 1362 1997 67–7676
tion following lipopolysaccharide stimulation is due
mainly to increased mRNA stability rather than in-
w xcreased transcription 19 .
These studies demonstrate an intriguing example
of a defective IL-6-induced response in association
with a common disease. This type of abnormality
would not be obvious in the basal state and would
only be detected during an acute-phase response.
Such abnormalities may occur in other acute phase
genes and particularly in those genes which play an
important role in inflammation.
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